Insulet Corporation (PODD) Maintains Buy Rating

Soleil Securities has released an update on Insulet Corporation (NASDAQ: PODD) following Friday’s FDA insulin pump meeting.

Following the meeting, Soleil expects more collaboration between the industry and the FDA to improve how all diabetes pump companies investigate and respond to problems with insulin pumps and communicate market actions, as well as best practices to help mitigate risks associated with these devices. Soleil believes that the company’s OmniPod disposable insulin pump system is easier to use than traditional durable pumps.

Soleil Securities continues to rate Insulet Corporation as a Buy, with a 12-month price target of $17.